Published in J Virol on August 01, 1996
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol (1999) 4.54
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A (2004) 3.60
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol (2006) 2.32
Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin Microbiol Rev (2006) 2.28
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol (2000) 2.00
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol (2006) 1.98
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol (2003) 1.94
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology (2004) 1.56
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol (1997) 1.55
Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol (1999) 1.52
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol (2008) 1.50
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med (1998) 1.49
Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res (2009) 1.48
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41
Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol (1997) 1.38
Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol (1999) 1.37
Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34
Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis. J Virol (1997) 1.31
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol (2007) 1.31
APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology (2009) 1.27
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. J Virol (1999) 1.26
The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol (1998) 1.20
Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system. J Virol (2004) 1.19
Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J Biol Chem (2009) 1.17
The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology (2007) 1.14
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res (2007) 1.07
APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology (2008) 1.04
Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import. Retrovirology (2005) 1.04
Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol (2002) 1.03
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol (2012) 1.03
Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. J Virol (2007) 1.03
Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol (2000) 1.02
Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One (2008) 1.01
APOBEC3G: a double agent in defense. Trends Biochem Sci (2011) 0.96
Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2. J Virol (2001) 0.94
Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol (1997) 0.94
Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res (2013) 0.92
Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol (2002) 0.91
Feline immunodeficiency virus Vif localizes to the nucleus. J Virol (2000) 0.90
Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res (2010) 0.90
Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol (2005) 0.89
Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif. J Virol (2004) 0.86
HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition. Blood (2010) 0.84
Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc Natl Acad Sci U S A (1998) 0.83
Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol (2001) 0.83
Characterization of producer cell-dependent restriction of murine leukemia virus replication. J Virol (2002) 0.82
Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology (2013) 0.82
Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages. Hum Gene Ther (2011) 0.82
APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells. J Virol (2013) 0.81
Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy. PLoS Comput Biol (2012) 0.80
APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study. PLoS One (2013) 0.79
The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation. Retrovirology (2015) 0.78
Controlling lentiviruses: single amino acid changes can determine specificity. Proc Natl Acad Sci U S A (2004) 0.76
Requirements for nucleocapsid-mediated regulation of reverse transcription during the late steps of HIV-1 assembly. Sci Rep (2016) 0.76
Evolution of the long terminal repeat and accessory genes of feline immunodeficiency virus genomes from naturally infected cougars. Virology (2007) 0.76
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature (1991) 6.79
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol (1992) 5.31
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol (1993) 5.30
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol (1992) 4.72
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41
Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25
The retroviral enzymes. Annu Rev Biochem (1994) 4.21
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol (1993) 4.16
Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science (1986) 4.04
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology (1994) 3.16
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
Transcription-dependent and transcription-independent nuclear transport of hnRNP proteins. Science (1991) 3.03
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
A quantitative bioassay for HIV-1 based on trans-activation. Science (1988) 2.99
Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses (1990) 2.67
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes (1992) 2.40
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol (1995) 2.25
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol (1995) 2.19
Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses (1994) 2.18
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol (1995) 2.17
Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A (1994) 2.09
The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology (1995) 2.08
Role of vif during packing of the core of HIV-1. Virology (1994) 2.01
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol (1995) 1.97
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol (1991) 1.72
Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. J Virol (1992) 1.59
Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr (1994) 1.58
The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line. Virology (1994) 1.37
The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. AIDS Res Hum Retroviruses (1993) 1.23
Growth ability of human immunodeficiency virus type 1 auxiliary gene mutants in primary blood macrophage cultures. J Gen Virol (1994) 1.22
Analysis of the vif gene of feline immunodeficiency virus. Virology (1994) 1.17
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
The HIV-1 Rev protein. Annu Rev Microbiol (1998) 4.78
Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med (1991) 4.56
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07
Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med (1998) 3.84
Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci U S A (1989) 3.43
The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev (1994) 3.34
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature (1988) 3.31
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science (1998) 3.28
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev (1989) 3.09
Reverse transcriptase activity and Ty RNA are associated with virus-like particles in yeast. Nature (1986) 3.07
Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol (1989) 2.89
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
HIV-1 infection requires a functional integrase NLS. Mol Cell (2001) 2.26
The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev (1992) 2.24
Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev (1990) 2.24
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci U S A (1992) 1.96
Importin beta can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin alpha. Mol Cell Biol (1999) 1.91
A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. Nucleic Acids Res (1990) 1.90
Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev. Proc Natl Acad Sci U S A (1996) 1.87
Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol (1992) 1.80
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol (1998) 1.70
The HIV-1 Rev protein: prototype of a novel class of eukaryotic post-transcriptional regulators. Trends Biochem Sci (1991) 1.67
Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv Virus Res (1999) 1.63
Phosphorylation of the rev gene product of human immunodeficiency virus type 1. J Virol (1988) 1.61
Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol (1999) 1.52
Differential regulation of CXCR4 and CCR5 endocytosis. J Cell Sci (1998) 1.49
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
The human T-cell leukemia virus type 1 posttranscriptional trans-activator Rex contains a nuclear export signal. J Virol (1996) 1.42
Conserved functional organization of the human immunodeficiency virus type 1 and visna virus Rev proteins. J Virol (1991) 1.41
Functional analysis of the Tat trans activator of human immunodeficiency virus type 2. J Virol (1989) 1.40
Expression strategies of the yeast retrotransposon Ty: a short sequence directs ribosomal frameshifting. Nucleic Acids Res (1986) 1.33
Complete nucleotide sequence of a mouse VL30 retro-element. Mol Cell Biol (1988) 1.23
Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1998) 1.19
Derivation of a biologically contained replication system for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.18
Sequence requirements for Rev multimerization in vivo. Virology (1994) 1.18
Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. J Virol (2000) 1.14
Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol (2001) 1.14
Intracellular trafficking of HIV-1 cores: journey to the center of the cell. Curr Top Microbiol Immunol (2003) 1.09
Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology (1998) 1.01
Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle. Nucleic Acids Res (1999) 1.01
Scanning mutagenesis of the arginine-rich region of the human immunodeficiency virus type 1 Rev trans activator. J Virol (1994) 0.93
Gold nanoparticle-mediated gene delivery induces widespread changes in the expression of innate immunity genes. Gene Ther (2011) 0.85
Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging. J Virol (2001) 0.82
The genetic organization of the yeast Ty element. J Cell Sci Suppl (1987) 0.80
Human placental alkaline phosphatase as a marker for gene expression. Methods Mol Biol (1997) 0.78